From emotion regulation to suicide-specific coping: a qualitative study of self-regulatory processes in suicidal crises.

Semaglutide is a once-daily oral or once-weekly injectable glucagon-like peptide-1 receptor agonist (GLP-1 RA) with regulatory approval for type 2 diabetes mellitus (T2DM) and, at higher doses, for obesity management. The oral formulation—Rybelsus, approved by the FDA in 2019—follows a standard titration: 3 mg daily for the first 4 weeks, then 7 mg, with a maximum of 14 mg for those requiring further glycaemic control (), GLP-1 receptors are not confined to the pancreas or gut. They are expressed in the prefrontal cortex, amygdala, hippocampus, and hypothalamus—brain regions that sit at the centre of mood regulation. Their activation alters the release of serotonin, dopamine, and glutamate, all of which play established roles in the pathophysiology of major depressive disorder (MDD) (). The psychiatric safety of semaglutide has been under regulatory scrutiny for some time. A analysis of the STEP 1–5 trials by Wadden et al. found that depressive symptoms serious enough to require clinical evaluation occurred in 2.8% of semaglutide-treated patients versus 4.1% with placebo—a finding that, at first glance, suggests a protective rather than harmful effect at the population level (). The pharmacovigilance data complicate that picture. A retrospective analysis of the FDA’s Adverse Event Reporting System (FAERS) identified disproportionality signals for semaglutide in both depression (reporting odds ratio [ROR]: 1.87; 95% confidence interval [CI]: 1.60–2.20) and suicide or self-injury events (ROR: 1.73; 95% CI: 1.46–2.04), concentrated in the 18–64 age range (). Population-level reassurance and individual-level risk are not the same thing, and this tension runs through the literature.